nodes	percent_of_prediction	percent_of_DWPC	metapath
Gemfibrozil—Peripheral vascular disorder—Varenicline—nicotine dependence	0.0628	0.0783	CcSEcCtD
Gemfibrozil—Musculoskeletal pain—Varenicline—nicotine dependence	0.0312	0.0389	CcSEcCtD
Gemfibrozil—Eczema—Varenicline—nicotine dependence	0.0249	0.031	CcSEcCtD
Gemfibrozil—Libido decreased—Varenicline—nicotine dependence	0.0241	0.0301	CcSEcCtD
Gemfibrozil—Atrial fibrillation—Varenicline—nicotine dependence	0.0236	0.0294	CcSEcCtD
Gemfibrozil—Disturbance in sexual arousal—Varenicline—nicotine dependence	0.0222	0.0277	CcSEcCtD
Gemfibrozil—Liver function test abnormal—Varenicline—nicotine dependence	0.0206	0.0257	CcSEcCtD
Gemfibrozil—Abdominal pain upper—Varenicline—nicotine dependence	0.0204	0.0255	CcSEcCtD
Gemfibrozil—Breast disorder—Varenicline—nicotine dependence	0.0202	0.0252	CcSEcCtD
Gemfibrozil—Nasopharyngitis—Varenicline—nicotine dependence	0.02	0.0249	CcSEcCtD
Gemfibrozil—CYP2C8—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0187	0.094	CbGpPWpGaD
Gemfibrozil—Erectile dysfunction—Varenicline—nicotine dependence	0.0178	0.0222	CcSEcCtD
Gemfibrozil—Photosensitivity reaction—Varenicline—nicotine dependence	0.0176	0.022	CcSEcCtD
Gemfibrozil—Depression—Varenicline—nicotine dependence	0.0172	0.0214	CcSEcCtD
Gemfibrozil—CYP2C19—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0166	0.0839	CbGpPWpGaD
Gemfibrozil—Hepatobiliary disease—Varenicline—nicotine dependence	0.0163	0.0203	CcSEcCtD
Gemfibrozil—Hypoaesthesia—Varenicline—nicotine dependence	0.0154	0.0192	CcSEcCtD
Gemfibrozil—Connective tissue disorder—Varenicline—nicotine dependence	0.0152	0.019	CcSEcCtD
Gemfibrozil—CYP2C9—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0152	0.0765	CbGpPWpGaD
Gemfibrozil—Eye disorder—Varenicline—nicotine dependence	0.0144	0.018	CcSEcCtD
Gemfibrozil—Mediastinal disorder—Varenicline—nicotine dependence	0.0139	0.0174	CcSEcCtD
Gemfibrozil—Mental disorder—Varenicline—nicotine dependence	0.0135	0.0169	CcSEcCtD
Gemfibrozil—Flatulence—Varenicline—nicotine dependence	0.0133	0.0165	CcSEcCtD
Gemfibrozil—Dysgeusia—Varenicline—nicotine dependence	0.0132	0.0164	CcSEcCtD
Gemfibrozil—Vision blurred—Varenicline—nicotine dependence	0.0127	0.0158	CcSEcCtD
Gemfibrozil—Anaemia—Varenicline—nicotine dependence	0.0124	0.0155	CcSEcCtD
Gemfibrozil—Angioedema—Varenicline—nicotine dependence	0.0123	0.0153	CcSEcCtD
Gemfibrozil—Vertigo—Varenicline—nicotine dependence	0.0121	0.0151	CcSEcCtD
Gemfibrozil—Syncope—Varenicline—nicotine dependence	0.0121	0.0151	CcSEcCtD
Gemfibrozil—Loss of consciousness—Varenicline—nicotine dependence	0.0118	0.0148	CcSEcCtD
Gemfibrozil—Cough—Varenicline—nicotine dependence	0.0117	0.0147	CcSEcCtD
Gemfibrozil—Convulsion—Varenicline—nicotine dependence	0.0117	0.0145	CcSEcCtD
Gemfibrozil—CYP2C8—Xenobiotics—CYP2A7—nicotine dependence	0.0116	0.0583	CbGpPWpGaD
Gemfibrozil—Chest pain—Varenicline—nicotine dependence	0.0115	0.0143	CcSEcCtD
Gemfibrozil—Myalgia—Varenicline—nicotine dependence	0.0115	0.0143	CcSEcCtD
Gemfibrozil—Arthralgia—Varenicline—nicotine dependence	0.0115	0.0143	CcSEcCtD
Gemfibrozil—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.0114	0.0142	CcSEcCtD
Gemfibrozil—Oedema—Varenicline—nicotine dependence	0.011	0.0137	CcSEcCtD
Gemfibrozil—Shock—Varenicline—nicotine dependence	0.0108	0.0135	CcSEcCtD
Gemfibrozil—Nervous system disorder—Varenicline—nicotine dependence	0.0108	0.0134	CcSEcCtD
Gemfibrozil—Thrombocytopenia—Varenicline—nicotine dependence	0.0108	0.0134	CcSEcCtD
Gemfibrozil—Skin disorder—Varenicline—nicotine dependence	0.0107	0.0133	CcSEcCtD
Gemfibrozil—CYP2C19—Xenobiotics—CYP2A7—nicotine dependence	0.0103	0.052	CbGpPWpGaD
Gemfibrozil—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.01	0.0125	CcSEcCtD
Gemfibrozil—Somnolence—Varenicline—nicotine dependence	0.00976	0.0122	CcSEcCtD
Gemfibrozil—Dyspepsia—Varenicline—nicotine dependence	0.00967	0.0121	CcSEcCtD
Gemfibrozil—PPARA—Orphan transporters—GABRA4—nicotine dependence	0.00953	0.0481	CbGpPWpGaD
Gemfibrozil—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00948	0.0118	CcSEcCtD
Gemfibrozil—Fatigue—Varenicline—nicotine dependence	0.00947	0.0118	CcSEcCtD
Gemfibrozil—CYP2C9—Xenobiotics—CYP2A7—nicotine dependence	0.00941	0.0474	CbGpPWpGaD
Gemfibrozil—Constipation—Varenicline—nicotine dependence	0.00939	0.0117	CcSEcCtD
Gemfibrozil—Pain—Varenicline—nicotine dependence	0.00939	0.0117	CcSEcCtD
Gemfibrozil—Feeling abnormal—Varenicline—nicotine dependence	0.00905	0.0113	CcSEcCtD
Gemfibrozil—Gastrointestinal pain—Varenicline—nicotine dependence	0.00898	0.0112	CcSEcCtD
Gemfibrozil—Urticaria—Varenicline—nicotine dependence	0.00873	0.0109	CcSEcCtD
Gemfibrozil—Abdominal pain—Varenicline—nicotine dependence	0.00868	0.0108	CcSEcCtD
Gemfibrozil—CYP1A2—Xenobiotics—CYP2A7—nicotine dependence	0.00804	0.0405	CbGpPWpGaD
Gemfibrozil—Asthenia—Varenicline—nicotine dependence	0.00788	0.00983	CcSEcCtD
Gemfibrozil—Pruritus—Varenicline—nicotine dependence	0.00777	0.00969	CcSEcCtD
Gemfibrozil—Diarrhoea—Varenicline—nicotine dependence	0.00752	0.00938	CcSEcCtD
Gemfibrozil—Dizziness—Varenicline—nicotine dependence	0.00726	0.00906	CcSEcCtD
Gemfibrozil—Vomiting—Varenicline—nicotine dependence	0.00698	0.00871	CcSEcCtD
Gemfibrozil—Rash—Varenicline—nicotine dependence	0.00693	0.00864	CcSEcCtD
Gemfibrozil—Dermatitis—Varenicline—nicotine dependence	0.00692	0.00863	CcSEcCtD
Gemfibrozil—Headache—Varenicline—nicotine dependence	0.00688	0.00858	CcSEcCtD
Gemfibrozil—Nausea—Varenicline—nicotine dependence	0.00652	0.00814	CcSEcCtD
Gemfibrozil—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.00621	0.0313	CbGpPWpGaD
Gemfibrozil—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.0048	0.0242	CbGpPWpGaD
Gemfibrozil—CYP2C8—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00474	0.0239	CbGpPWpGaD
Gemfibrozil—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00429	0.0216	CbGpPWpGaD
Gemfibrozil—CYP2C19—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00423	0.0213	CbGpPWpGaD
Gemfibrozil—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00391	0.0197	CbGpPWpGaD
Gemfibrozil—CYP2C8—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00389	0.0196	CbGpPWpGaD
Gemfibrozil—CYP2C9—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00386	0.0194	CbGpPWpGaD
Gemfibrozil—PPARA—Circadian rythm related genes—CHRNB2—nicotine dependence	0.0036	0.0181	CbGpPWpGaD
Gemfibrozil—CYP2C19—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00347	0.0175	CbGpPWpGaD
Gemfibrozil—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00334	0.0168	CbGpPWpGaD
Gemfibrozil—CYP1A2—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00329	0.0166	CbGpPWpGaD
Gemfibrozil—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00317	0.016	CbGpPWpGaD
Gemfibrozil—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00271	0.0136	CbGpPWpGaD
Gemfibrozil—PPARA—Circadian rythm related genes—DRD2—nicotine dependence	0.00266	0.0134	CbGpPWpGaD
Gemfibrozil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00258	0.013	CbGpPWpGaD
Gemfibrozil—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00254	0.0128	CbGpPWpGaD
Gemfibrozil—PPARA—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.00233	0.0117	CbGpPWpGaD
Gemfibrozil—CYP2C8—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00219	0.0111	CbGpPWpGaD
Gemfibrozil—PPARA—Gene Expression—CCAR1—nicotine dependence	0.00218	0.011	CbGpPWpGaD
Gemfibrozil—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00209	0.0105	CbGpPWpGaD
Gemfibrozil—CYP2C8—Biological oxidations—CYP2A7—nicotine dependence	0.00207	0.0104	CbGpPWpGaD
Gemfibrozil—CYP2C8—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00204	0.0103	CbGpPWpGaD
Gemfibrozil—CYP2C19—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00196	0.00987	CbGpPWpGaD
Gemfibrozil—CYP2C19—Biological oxidations—CYP2A7—nicotine dependence	0.00185	0.0093	CbGpPWpGaD
Gemfibrozil—CYP2C19—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00182	0.00917	CbGpPWpGaD
Gemfibrozil—CYP2C9—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00178	0.009	CbGpPWpGaD
Gemfibrozil—CYP2C9—Biological oxidations—CYP2A7—nicotine dependence	0.00168	0.00848	CbGpPWpGaD
Gemfibrozil—CYP2C9—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00166	0.00836	CbGpPWpGaD
Gemfibrozil—CYP1A2—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00153	0.00769	CbGpPWpGaD
Gemfibrozil—CYP1A2—Biological oxidations—CYP2A7—nicotine dependence	0.00144	0.00725	CbGpPWpGaD
Gemfibrozil—CYP1A2—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00142	0.00715	CbGpPWpGaD
Gemfibrozil—SLCO1B1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.00131	0.00662	CbGpPWpGaD
Gemfibrozil—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00118	0.00593	CbGpPWpGaD
Gemfibrozil—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.00111	0.00559	CbGpPWpGaD
Gemfibrozil—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00109	0.00552	CbGpPWpGaD
Gemfibrozil—PPARA—Metabolism—CYP2A7—nicotine dependence	0.00109	0.00549	CbGpPWpGaD
Gemfibrozil—SLCO1B1—Metabolism—CYP2A7—nicotine dependence	0.000615	0.0031	CbGpPWpGaD
Gemfibrozil—CYP2C8—Metabolism—CYP2A7—nicotine dependence	0.000354	0.00178	CbGpPWpGaD
Gemfibrozil—CYP2C19—Metabolism—CYP2A7—nicotine dependence	0.000316	0.00159	CbGpPWpGaD
Gemfibrozil—CYP2C9—Metabolism—CYP2A7—nicotine dependence	0.000288	0.00145	CbGpPWpGaD
Gemfibrozil—CYP1A2—Metabolism—CYP2A7—nicotine dependence	0.000246	0.00124	CbGpPWpGaD
Gemfibrozil—CYP3A4—Metabolism—CYP2A7—nicotine dependence	0.00019	0.000956	CbGpPWpGaD
